Abstract
Vascular calcification, both in the coronary and in the peripheral arteries, is associated with increased cardiovascular (CV) risk. However, agents that prevent vascular calcification (e.g. estrogens or calcimimetic agents) might have neutral or detrimental effects on CV events. Moreover, statins and antihypertensive agents do not appear to modify vascular calcification, despite their established benefits on CV disease prevention. On the other hand, recent data suggest that microRNAs play a role in the regulation of vascular calcification. It is therefore possible that modulation of the expression of microRNAs might represent a useful strategy for preventing or delaying the progression of this process.
Keywords: Vascular calcification, cardiovascular risk, microRNA, statins, coronary artery calcium, aortic stenosis.
Current Vascular Pharmacology
Title:Editorial: Vascular Calcification, Cardiovascular Risk and microRNAs
Volume: 14 Issue: 2
Author(s): Konstantinos Tziomalos, Vasilios G. Athyros and Asterios Karagiannis
Affiliation:
Keywords: Vascular calcification, cardiovascular risk, microRNA, statins, coronary artery calcium, aortic stenosis.
Abstract: Vascular calcification, both in the coronary and in the peripheral arteries, is associated with increased cardiovascular (CV) risk. However, agents that prevent vascular calcification (e.g. estrogens or calcimimetic agents) might have neutral or detrimental effects on CV events. Moreover, statins and antihypertensive agents do not appear to modify vascular calcification, despite their established benefits on CV disease prevention. On the other hand, recent data suggest that microRNAs play a role in the regulation of vascular calcification. It is therefore possible that modulation of the expression of microRNAs might represent a useful strategy for preventing or delaying the progression of this process.
Export Options
About this article
Cite this article as:
Tziomalos Konstantinos, Athyros G. Vasilios and Karagiannis Asterios, Editorial: Vascular Calcification, Cardiovascular Risk and microRNAs, Current Vascular Pharmacology 2016; 14 (2) . https://dx.doi.org/10.2174/157016111402160208150816
DOI https://dx.doi.org/10.2174/157016111402160208150816 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Hot Topic: Modifying Cardiovascular Risk Factors: New Markers of Cardiovascular Damage)
Current Pharmaceutical Design Personalized Medicine, Bioethics and Social Responsibilities: Re-thinking the Pharmaceutical Industry to Remedy Inequities in Patient Care and International Health
Current Pharmacogenomics and Personalized Medicine Agave (Agave spp.) and its Traditional Products as a Source of Bioactive Compounds
Current Bioactive Compounds The Histamine H3 Receptor as a Therapeutic Drug Target for Metabolic Disorders: Status, Challenges and Opportunities
Current Topics in Medicinal Chemistry Medicinal Agents and Metabolic Syndrome
Current Medicinal Chemistry Herbal and Traditional Chinese Medicine for the Treatment of Cardiovascular Complications in Diabetes Mellitus
Current Diabetes Reviews Anti-Inflammatory Effects of Fibrates: An Overview
Current Medicinal Chemistry Relevance of Nutritional Antioxidants in Metabolic Syndrome, Ageing and Cancer: Potential for Therapeutic Targeting
Infectious Disorders - Drug Targets Current Concepts on Cardiovascular Stent Devices
Mini-Reviews in Medicinal Chemistry Endoplasmic Reticulum Stress as a Novel Therapeutic Target in Heart Diseases
Cardiovascular & Hematological Disorders-Drug Targets Flavonoids: Prospective Drug Candidates
Mini-Reviews in Medicinal Chemistry Expression and Functions of Vasoactive Substances Regulated by Hypoxia-Inducible Factor-1 in Chronic Hypoxemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Graphical Abstracts
Letters in Drug Design & Discovery Phytogenic Polyphenols as Glycogen Phosphorylase Inhibitors: The Potential of Triterpenes and Flavonoids for Glycaemic Control in Type 2 Diabetes
Current Medicinal Chemistry Potentiating the Naturally Occurring Process for Repair of Damaged Heart
Current Pharmaceutical Design Asymmetric Dimethylarginine (ADMA) and Cardiovascular Disease
Vascular Disease Prevention (Discontinued) Chitosan Nanoparticles: An Approbative System for the Delivery of Herbal Bioactives
The Natural Products Journal Dyslipidaemia, Hypercoagulability and the Metabolic Syndrome
Current Vascular Pharmacology Energy Expenditure of Hunter-Gatherers: When Statistics Turns to be Unreliable
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Perspective for Antithrombotic Therapy in TAVI
Current Pharmaceutical Design